Maryland 2025 Regular Session

Maryland House Bill HB1084 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3	EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
4	4	[Brackets] indicate matter deleted from existing law.
5	5	hb1084
6	6
7	7	HOUSE BILL 1084
8	8	E5 5lr3426
9	9	SB 801/24 – B&T & JPR CF SB 942
10	10	By: Delegates Pena–Melnyk, Cullison, and White Holland
11	11	Introduced and read first time: February 5, 2025
12	12	Assigned to: Judiciary and Health and Government Operations
13	13
14	14	A BILL ENTITLED
15	15
16	16	AN ACT concerning 1
17	17
18	18	Correctional Services – Medication–Assisted Treatment Funding 2
19	19
20	20	FOR the purpose of repealing the requirement that each local correctional facility make 3
21	21	available at least one formulation of certain Food and Drug 4
22	22	Administration–approved opioid medications used for the treatment of opioid use 5
23	23	disorders; requiring the Maryland Secretary of Health to provide annually each 6
24	24	county a grant equal to the costs incurred by the county for the implementation of a 7
25	25	certain medication–assisted treatment program; authorizing the Governor to include 8
26	26	in the annual budget bill an appropriation for the purpose of providing grants under 9
27	27	certain circumstances; expanding the authorized uses of the Opioid Restitution 10
28	28	Fund; and generally relating to medication–assisted treatment for incarcerated 11
29	29	individuals. 12
30	30
31	31	BY repealing and reenacting, with amendments, 13
32	32	Article – Correctional Services 14
33	33	Section 9–603 15
34	34	Annotated Code of Maryland 16
35	35	(2017 Replacement Volume and 2024 Supplement) 17
36	36
37	37	BY repealing and reenacting, with amendments, 18
38	38	Article – State Finance and Procurement 19
39	39	Section 7–331 20
40	40	Annotated Code of Maryland 21
41	41	(2021 Replacement Volume and 2024 Supplement) 22
42	42
43	43	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 23
44	44	That the Laws of Maryland read as follows: 24
45	45
46	46	Article – Correctional Services 25
47	47
48	48	9–603. 26 2 HOUSE BILL 1084
49	49
50	50
51	51
52	52	(a) (1) Subject to paragraph (2) of this subsection, the requirements under this 1
53	53	section shall apply to: 2
54	54
55	55	(i) local detention centers in the following counties by January 1, 3
56	56	2020: 4
57	57
58	58	1. Howard County; 5
59	59
60	60	2. Montgomery County; 6
61	61
62	62	3. Prince George’s County; and 7
63	63
64	64	4. St. Mary’s County; and 8
65	65
66	66	(ii) local detention centers in six additional counties by October 1, 9
67	67	2021. 10
68	68
69	69	(2) (i) The Governor’s Office of Crime Prevention and Policy, the 11
70	70	Maryland Department of Health, and the Maryland Correctional Administrators 12
71	71	Association shall evaluate the implementation of the requirements of this section and 13
72	72	determine a schedule to add additional counties, provided that the provisions of this section 14
73	73	shall apply to all local detention centers and the Baltimore Pre–trial Complex by January 15
74	74	2023. 16
75	75
76	76	(ii) If the Baltimore Pre–trial Complex has not fully implemented 17
77	77	the provisions of this section by January 2023, the Department of Public Safety and 18
78	78	Correctional Services shall report to the Senate Finance Committee and the House 19
79	79	Judiciary Committee, in accordance with § 2–1257 of the State Government Article, on the 20
80	80	status and timeline of implementation. 21
81	81
82	82	(iii) Funding for the program at the Baltimore Pre–trial Complex 22
83	83	shall be as provided in the State budget. 23
84	84
85	85	(b) (1) In this section the following words have the meanings indicated. 24
86	86
87	87	(2) “Health care practitioner” means an individual who is licensed, 25
88	88	certified, or otherwise authorized to practice under the Health Occupations Article. 26
89	89
90	90	(3) “Incarcerated individual” means an individual confined within a local 27
91	91	correctional facility. 28
92	92
93	93	(4) “Medication” means a medication approved by the federal Food and 29
94	94	Drug Administration for the treatment of opioid use disorder. 30
95	95	HOUSE BILL 1084 3
96	96
97	97
98	98	(5) “Medication–assisted treatment” means the use of medication, in 1
99	99	combination with counseling and behavioral health therapies, to provide a holistic 2
100	100	approach to the treatment of opioid use disorder. 3
101	101
102	102	(6) “Opioid use disorder” means a medically diagnosed problematic pattern 4
103	103	of opioid use that causes significant impairment or distress. 5
104	104
105	105	(7) “Peer recovery specialist” means an individual who has been certified 6
106	106	by an entity approved by the Maryland Department of Health for the purpose of providing 7
107	107	peer support services, as defined under § 7.5–101(n) of the Health – General Article. 8
108	108
109	109	(c) An incarcerated individual in a State or local correctional facility shall be 9
110	110	placed on a properly supervised program of methadone detoxification if: 10
111	111
112	112	(1) a physician determines that the incarcerated individual is a person 11
113	113	with an opioid use disorder; 12
114	114
115	115	(2) the treatment is prescribed by a physician; and 13
116	116
117	117	(3) the incarcerated individual consents in writing to the treatment. 14
118	118
119	119	(d) (1) Each local correctional facility shall conduct an assessment of the 15
120	120	mental health and substance use status of each incarcerated i ndividual using 16
121	121	evidence–based screenings and assessments, to determine: 17
122	122
123	123	(i) if the medical diagnosis of an opioid use disorder is appropriate; 18
124	124	and 19
125	125
126	126	(ii) if medication–assisted treatment is appropriate. 20
127	127
128	128	(2) If an assessment conducted under paragraph (1) of this subsection 21
129	129	indicates opioid use disorder, an evaluation of the incarcerated individual shall be 22
130	130	conducted by a health care practitioner with prescriptive authority authorized under Title 23
131	131	8, Title 14, or Title 15 of the Health Occupations Article. 24
132	132
133	133	(3) Information shall be provided to the incarcerated individual describing 25
134	134	medication options used in medication–assisted treatment. 26
135	135
136	136	(4) Medication–assisted treatment shall be available to an incarcerated 27
137	137	individual for whom such treatment is determined to be appropriate under this subsection. 28
138	138
139	139	(5) [Each local correctional facility shall make available at least one 29
140	140	formulation of each FDA–approved full opioid agonist, partial opioid agonist, and 30
141	141	long–acting opioid antagonist used for the treatment of opioid use disorders. 31
142	142
143	143	(6)] Each pregnant woman identified with an opioid use disorder shall 32
144	144	receive evaluation and be offered medication–assisted treatment as soon as practicable. 33 4 HOUSE BILL 1084
145	145
146	146
147	147
148	148	(e) Each local correctional facility shall: 1
149	149
150	150	(1) following an assessment using clinical guidelines for 2
151	151	medication–assisted treatment: 3
152	152
153	153	(i) make medication available by a qualified provider to the 4
154	154	incarcerated individual; or 5
155	155
156	156	(ii) begin withdrawal management services prior to administration 6
157	157	of medication; 7
158	158
159	159	(2) make available and administer medications for the treatment of opioid 8
160	160	use disorder; 9
161	161
162	162	(3) provide behavioral health counseling for incarcerated individuals 10
163	163	diagnosed with opioid use disorder consistent with therapeutic standards for such therapies 11
164	164	in a community setting; 12
165	165
166	166	(4) provide access to a health care practitioner who can provide access to 13
167	167	all FDA–approved medications for the treatment of opioid use disorders; and 14
168	168
169	169	(5) provide on–premises access to peer recovery specialists. 15
170	170
171	171	(f) If an incarcerated individual received medication or medication–assisted 16
172	172	treatment for opioid use disorder immediately preceding or during the incarcerated 17
173	173	individual’s incarceration, a local correctional facility shall continue the treatment after 18
174	174	incarceration or transfer unless: 19
175	175
176	176	(1) the incarcerated individual voluntarily discontinues the treatment, 20
177	177	verified through a written agreement that includes a signature; or 21
178	178
179	179	(2) a health care practitioner determines that the treatment is no longer 22
180	180	medically appropriate. 23
181	181
182	182	(g) Before the release of an incarcerated individual diagnosed with opioid use 24
183	183	disorder under subsection (d) of this section, a local correctional facility shall develop a plan 25
184	184	of reentry that: 26
185	185
186	186	(1) includes information regarding postincarceration access to medication 27
187	187	continuity, peer recovery specialists, other supportive therapy, and enrollment in health 28
188	188	insurance plans; 29
189	189
190	190	(2) includes any recommended referrals by a health care practitioner to 30
191	191	medication continuity, peer recovery specialists, and other supportive therapy; and 31
192	192	HOUSE BILL 1084 5
193	193
194	194
195	195	(3) is reviewed and, if needed, revised by a health care practitioner or peer 1
196	196	recovery specialist. 2
197	197
198	198	(h) The procedures and standards used to determine substance use disorder 3
199	199	diagnosis and treatment of incarcerated individuals are subject to the guidelines and 4
200	200	regulations adopted by the Maryland Department of Health. 5
201	201
202	202	[(i) As provided in the State budget, the State shall fund the program of opioid 6
203	203	use disorder screening, evaluation, and treatment of incarcerated individuals as provided 7
204	204	under this section.] 8
205	205
206	206	(I) (1) SUBJECT TO SUBSECTION (J) OF THIS SECTION, FOR EACH FISCAL 9
207	207	YEAR THE SECRETARY OF HEALTH THROUGH THE OFFICE OF OVERDOSE 10
208	208	RESPONSE SHALL PROVID E EACH COUNTY A GRAN T EQUAL TO THE COSTS 11
209	209	INCURRED BY THE COU NTY FOR THE IMPLEMEN TATION OF A 12
210	210	MEDICATION–ASSISTED TREATMENT P ROGRAM IN ACCORDANCE WITH THIS 13
211	211	SECTION DURING THE P RECEDING FISCAL YEAR . 14
212	212
213	213	(2) THE SECRETARY OF HEALTH, IN CONSULTATION WITH THE 15
214	214	OFFICE OF OVERDOSE RESPONSE, SHALL PROVIDE A GRAN T UNDER PARAGRAPH 16
215	215	(1) OF THIS SUBSECTION F ROM: 17
216	216
217	217	(I) THE OPIOID RESTITUTION FUND ESTABLISHED UNDE R § 18
218	218	7–331 OF THE STATE FINANCE AND PROCUREMENT ARTICLE; AND 19
219	219
220	220	(II) ANY MONEY APPROPRIAT ED IN THE STATE BUDGET FOR 20
221	221	THE PURPOSE OF PROVI DING GRANTS UNDER TH IS SUBSECTION. 21
222	222
223	223	(3) FUNDS DISTRIBUTED UNDER THIS SUBSECTION MAY BE REDUCED 22
224	224	BY THE AMOUNT OF AN AWARD FROM THE GOVERNOR’S OFFICE OF CRIME 23
225	225	PREVENTION AND POLICY OR THE MARYLAND DEPARTMENT OF HEALTH, OR A 24
226	226	FEDERAL AWARD FOR THE SAME PURPOSES . 25
227	227
228	228	(J) (1) ON OR BEFORE OCTOBER 1 EACH YEAR, EACH COUNTY SHALL 26
229	229	SUBMIT TO THE OFFICE OF OVERDOSE RESPONSE A REPORT ON : 27
230	230
231	231	(I) THE NUMBER OF DAYS E ACH INCARCERATED IND IVIDUAL 28
232	232	WAS PROVIDED A SERVI CE UNDER A MEDICATIO N–ASSISTED TREATMENT P ROGRAM 29
233	233	IN ACCORDANCE WITH T HIS SECTION DURI NG THE PREVIOUS FISC AL YEAR; 30
234	234
235	235	(II) THE TOTAL ITEMIZED C OSTS INCURRED FOR 31
236	236	MEDICATION–ASSISTED TREATMENT S ERVICES BY EACH LOCA L CORRECTIONAL 32
237	237	FACILITY; AND 33
238	238	6 HOUSE BILL 1084
239	239
240	240
241	241	(III) ANY OTHER INFORMATIO N THAT THE OFFICE OF OVERDOSE 1
242	242	RESPONSE REQUIRES . 2
243	243
244	244	(2) IF A COUNTY F AILS TO SUBMIT THE I NFORMATION REQUIRED 3
245	245	UNDER PARAGRAPH (1) OF THIS SUBSECTION W HEN DUE, THE SECRETARY OF 4
246	246	HEALTH SHALL DEDUCT A N AMOUNT EQUAL TO 20% OF ANY GRANT AWARDED 5
247	247	UNDER SUBSECTION (I) OF THIS SECTION FOR EACH 30 DAYS OR PART OF 30 DAYS 6
248	248	AFTER THE DUE DATE THAT THE INFORM ATION WAS NOT SUBMIT TED. 7
249	249
250	250	(K) (1) THE GOVERNOR MAY INCLUDE IN THE ANNUAL BUDGET BILL AN 8
251	251	APPROPRIATION TO THE MARYLAND DEPARTMENT OF HEALTH FOR THE PURPOSE 9
252	252	OF PROVIDING GRANTS UNDER SUBSECTION (I) OF THIS SECTION. 10
253	253
254	254	(2) AN APPROPRIATION UNDER THIS SUBSECTION MAY BE USED ONLY 11
255	255	TO PROVIDE FUNDING EQUAL TO THE COSTS INCURRED BY A COUNTY FOR THE 12
256	256	IMPLEMENTATION OF A MEDICATION –ASSISTED TREATMENT PROGRAM IN 13
257	257	ACCORDANCE WITH THIS SECTION. 14
258	258
259	259	[(j)] (L) On or before November 1, 2020, and annually thereafter, the Governor’s 15
260	260	Office of Crime Prevention and Policy shall report data from individual local correctional 16
261	261	facilities to the General Assembly, in accordance with § 2–1257 of the State Government 17
262	262	Article, on: 18
263	263
264	264	(1) the number of incarcerated individuals diagnosed with: 19
265	265
266	266	(i) a mental health disorder; 20
267	267
268	268	(ii) an opioid use disorder; 21
269	269
270	270	(iii) a non–opioid substance use disorder; and 22
271	271
272	272	(iv) a dual diagnosis of mental health and substance use disorder; 23
273	273
274	274	(2) the number and cost of assessments for incarcerated individuals in local 24
275	275	correctional facilities, including the number of unique incarcerated individuals examined; 25
276	276
277	277	(3) the number of incarcerated individuals who were receiving medication 26
278	278	or medication–assisted treatment for opioid use disorder immediately prior to 27
279	279	incarceration; 28
280	280
281	281	(4) the type and prevalence of medication or medication –assisted 29
282	282	treatments for opioid use disorder provided; 30
283	283
284	284	(5) the number of incarcerated individuals diagnosed with opioid use 31
285	285	disorder; 32
286	286	HOUSE BILL 1084 7
287	287
288	288
289	289	(6) the number of incarcerated individuals for whom medication and 1
290	290	medication–assisted treatment for opioid use disorder was prescribed; 2
291	291
292	292	(7) the number of incarcerated individuals for whom medication and 3
293	293	medication–assisted treatment was prescribed and initiated for opioid use disorder; 4
294	294
295	295	(8) the number of medications and medication–assisted treatments for 5
296	296	opioid use disorder provided according to each type of medication and medication–assisted 6
297	297	treatment options; 7
298	298
299	299	(9) the number of incarcerated individuals who continued to receive the 8
300	300	same medication or medication–assisted treatment for opioid use disorder as the 9
301	301	incarcerated individual received prior to incarceration; 10
302	302
303	303	(10) the number of incarcerated individuals who received a different 11
304	304	medication or medication–assisted treatment for opioid use disorder compared to what the 12
305	305	incarcerated individual received prior to incarceration; 13
306	306
307	307	(11) the number of incarcerated individuals who initiated treatment with 14
308	308	medication or medication–assisted treatment for opioid use disorder who were not being 15
309	309	treated for opioid use disorder prior to incarceration; 16
310	310
311	311	(12) the number of incarcerated individuals who discontinued medication or 17
312	312	medication–assisted treatment for opioid use disorder during incarceration; 18
313	313
314	314	(13) [a review and summary of the percent of days, including the average 19
315	315	percent, median percent, mode percent, and interquartile range of percent, for incarcerated 20
316	316	individuals with opioid use disorder receiving medication or medication–assisted treatment 21
317	317	for opioid use disorder as calculated overall and stratified by other factors, such as type of 22
318	318	treatment received] THE AVERAGE NUMBER OF DAYS INCARCERATED INDIVIDUALS 23
319	319	RECEIVED MEDICATION –ASSISTED TREATMENT IN ACCORDANCE WITH THIS 24
320	320	SECTION; 25
321	321
322	322	(14) the number of incarcerated individuals receiving medication or 26
323	323	medication–assisted treatment for opioid use disorder prior to release; 27
324	324
325	325	(15) the number of incarcerated individuals receiving medication or 28
326	326	medication–assisted treatment prior to release for whom the facility had made a prerelease 29
327	327	reentry plan; 30
328	328
329	329	(16) a review and summary of practices related to medication and 31
330	330	medication–assisted treatment for opioid use disorder for incarcerated individuals with 32
331	331	opioid use disorder before October 1, 2019; 33
332	332
333	333	(17) a review and summary of prerelease planning practices relative to 34
334	334	incarcerated individuals diagnosed with opioid use disorder prior to, and following, October 35
335	335	1, 2019; [and] 36 8 HOUSE BILL 1084
336	336
337	337
338	338
339	339	(18) THE TOTAL ITEMIZED COSTS INCURRED FOR 1
340	340	MEDICATION–ASSISTED TREATMENT SERVICES BY EACH LOCAL CORRECTIONAL 2
341	341	FACILITY; AND 3
342	342
343	343	[(18)] (19) any other information requested by the [Maryland Department 4
344	344	of Health] OFFICE OF OVERDOSE RESPONSE related to the administration of the 5
345	345	provisions under this section. 6
346	346
347	347	[(k)] (M) Any behavioral health assessment, evaluation, treatment 7
348	348	recommendation, or course of treatment shall be reported to the Governor’s Office of Crime 8
349	349	Prevention and Policy and also include any other data necessary to meet reporting 9
350	350	requirements under this section. 10
351	351
352	352	Article – State Finance and Procurement 11
353	353
354	354	7–331. 12
355	355
356	356	(a) In this section, “Fund” means the Opioid Restitution Fund. 13
357	357
358	358	(b) There is an Opioid Restitution Fund. 14
359	359
360	360	(c) The purpose of the Fund is to retain the amount of settlement revenues 15
361	361	deposited to the Fund in accordance with subsection (e)(1) of this section. 16
362	362
363	363	(d) (1) The Fund is a special, nonlapsing fund that is not subject to § 7–302 of 17
364	364	this subtitle. 18
365	365
366	366	(2) The State Treasurer shall hold the Fund separately, and the 19
367	367	Comptroller shall account for the Fund. 20
368	368
369	369	(e) The Fund consists of: 21
370	370
371	371	(1) all revenues received by the State from any source resulting, directly or 22
372	372	indirectly, from any judgment against, or settlement with, opioid manufacturers, opioid 23
373	373	research associations, or any other person in the opioid industry relating to any claims 24
374	374	made or prosecuted by the State to recover damages for violations of State law; and 25
375	375
376	376	(2) the interest earnings of the Fund. 26
377	377
378	378	(f) The Fund may be used only to provide funds for: 27
379	379
380	380	(1) programs, services, supports, and resources for evidence–based 28
381	381	substance use disorder prevention, treatment, recovery, or harm reduction that have the 29
382	382	purpose of: 30
383	383	HOUSE BILL 1084 9
384	384
385	385
386	386	(i) improving access to medications proven to prevent or reverse an 1
387	387	overdose, including by supporting the initiative to co–locate naloxone with automated 2
388	388	external defibrillators placed in public buildings under § 13–518 of the Education Article; 3
389	389
390	390	(ii) supporting peer support specialists and screening, brief 4
391	391	intervention, and referral to treatment services for hospitals, correctional facilities, and 5
392	392	other high–risk populations; 6
393	393
394	394	(iii) increasing access to medications that support recovery from 7
395	395	substance use disorders; 8
396	396
397	397	(iv) expanding the Heroin Coordinator Program, including for 9
398	398	administrative expenses; 10
399	399
400	400	(v) expanding access to crisis beds and residential treatment 11
401	401	services for adults and minors; 12
402	402
403	403	(vi) expanding and establishing safe stations, mobile crisis response 13
404	404	systems, and crisis stabilization centers; 14
405	405
406	406	(vii) supporting the behavioral health crisis hotline; 15
407	407
408	408	(viii) organizing primary and secondary school education campaigns 16
409	409	to prevent opioid use, including for administrative expenses; 17
410	410
411	411	(ix) enforcing the laws regarding opioid prescriptions and sales, 18
412	412	including for administrative expenses; 19
413	413
414	414	(x) research regarding and training for substance use treatment and 20
415	415	overdose prevention, including for administrative expenses; and 21
416	416
417	417	(xi) supporting and expanding other evidence–based interventions 22
418	418	for overdose prevention and substance use treatment; 23
419	419
420	420	(2) supporting community–based nonprofit recovery organizations that 24
421	421	provide nonclinical substance use recovery support services in the State; 25
422	422
423	423	(3) evidence–informed substance use disorder prevention, treatment 26
424	424	recovery, or harm reduction pilot programs or demonstration studies that are not 27
425	425	evidence–based if the Opioid Restitution Fund Advisory Council, established under § 28
426	426	7.5–902 of the Health – General Article: 29
427	427
428	428	(i) determines that emerging evidence supports the distribution of 30
429	429	money for the pilot program or that there is a reasonable basis for funding the 31
430	430	demonstration study with the expectation of creating an evidence–based program; and 32
431	431	10 HOUSE BILL 1084
432	432
433	433
434	434	(ii) approves the use of money for the pilot program or demonstration 1
435	435	study; [and] 2
436	436
437	437	(4) evaluations of the effectiveness and outcomes reporting for substance 3
438	438	use disorder abatement infrastructure, programs, services, supports, and resources for 4
439	439	which money from the Fund was used, including evaluations of the impact on access to 5
440	440	harm reduction services or treatment for substance use disorders and the reduction in 6
441	441	drug–related mortality; AND 7
442	442
443	443	(5) GRANTS TO COUNTIES F OR THE IMPLEMENTATIO N OF A 8
444	444	MEDICATION–ASSISTED TREATMENT P ROGRAM UNDER TITLE 9, SUBTITLE 6 OF THE 9
445	445	CORRECTIONAL SERVICES ARTICLE. 10
446	446
447	447	(g) (1) The State Treasurer shall invest the money of the Fund in the same 11
448	448	manner as other State money may be invested. 12
449	449
450	450	(2) Any interest earnings of the Fund shall be credited to the Fund. 13
451	451
452	452	(h) (1) Expenditures from the Fund may be made only in accordance with the 14
453	453	State budget. 15
454	454
455	455	(2) For settlement funds received in accordance with the final distributor 16
456	456	agreement of July 21, 2021, with McKesson Corporation, Amerisource Bergen Corporation, 17
457	457	and Cardinal Health Incorporated, as amended, the Janssen settlement agreement of July 18
458	458	21, 2021, as amended, or any other opioid–related court or administrative judgment or 19
459	459	settlement agreement involving the State and one or more of its political subdivisions: 20
460	460
461	461	(i) appropriations from the Fund in the State budget shall be made 21
462	462	in accordance with the allocation and distribution of funds to the State and its political 22
463	463	subdivisions: 23
464	464
465	465	1. as agreed on in the State–subdivision agreement of 24
466	466	January 21, 2022, as amended; or 25
467	467
468	468	2. required under any other opioid –related court or 26
469	469	administrative judgment or settlement agreement, or any similar agreement reached under 27
470	470	an opioid–related court or administrative judgment or settlement agreement, involving the 28
471	471	State and one or more of its political subdivisions; and 29
472	472
473	473	(ii) the Secretary of Health shall establish and administer a grant 30
474	474	program for the distribution of funds to political subdivisions of the State in accordance 31
475	475	with: 32
476	476
477	477	1. the State–subdivision agreement of January 21, 2022, as 33
478	478	amended; or 34
479	479	HOUSE BILL 1084 11
480	480
481	481
482	482	2. the requirements of any other opioid–related court or 1
483	483	administrative judgment or settlement agreement, or any similar agreement reached under 2
484	484	an opioid–related court or administrative judgment or settlement agreement, involving the 3
485	485	State and one or more of its political subdivisions. 4
486	486
487	487	(3) The Attorney General shall identify and designate the controlling 5
488	488	version of any agreement or amendment described under paragraph (2) of this subsection. 6
489	489
490	490	(i) (1) Money expended from the Fund for the programs and services described 7
491	491	under subsection (f) of this section is supplemental to and is not intended to take the place 8
492	492	of funding that otherwise would be appropriated for the programs and services. 9
493	493
494	494	(2) Except as specified in subsection (f) of this section, money expended 10
495	495	from the Fund may not be used for administrative expenses. 11
496	496
497	497	(j) The Governor shall: 12
498	498
499	499	(1) develop key goals, key objectives, and key performance indicators 13
500	500	relating to substance use treatment and prevention efforts; 14
501	501
502	502	(2) subject to subsection (h)(2) of this section, at least twice annually, 15
503	503	consult with the Opioid Restitution Fund Advisory Council to identify recommended 16
504	504	appropriations from the Fund; and 17
505	505
506	506	(3) report on or before November 1 each year, in accordance with § 2–1257 18
507	507	of the State Government Article, to the General Assembly on: 19
508	508
509	509	(i) an accounting of total funds expended from the Fund in the 20
510	510	immediately preceding fiscal year, by: 21
511	511
512	512	1. use; 22
513	513
514	514	2. if applicable, jurisdiction; and 23
515	515
516	516	3. budget program and subdivision; 24
517	517
518	518	(ii) the performance indicators and progress toward achieving the 25
519	519	goals and objectives developed under item (1) of this subsection; and 26
520	520
521	521	(iii) the recommended appropriations from the Fund identified in 27
522	522	accordance with item (2) of this subsection. 28
523	523
524	524	SECTION 2. AND BE IT FURTHER ENACTED, That this Act s hall take effect 29
525	525	October 1, 2025. 30